Rapamycin for treatment of tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: report of two cases and review of literature

VernacularTitle:雷帕霉素治疗酪氨酸激酶抑制剂耐药慢性粒细胞白血病二例并文献复习
Author: Jing XIE ¹ ; Zhengyuan LIU ; Xiaoqing LIU ; Lang CHENG ; Guangsheng HE ; Jianyong LI
Author Information

1. 江苏省泰兴市人民医院血液科　225400
From: Journal of Leukemia & Lymphoma 2020;29(11):684-687
CountryChina
Language:Chinese
Abstract: Objective:To investigate the effect of rapamycin in treatment of tyrosine kinase inhibitor (TKI)-resistant chronic myelogenous leukemia (CML) without ABL mutation.Methods:Flow cytometry was used to detect the positive expressions of p-mTOR and p-S6 in CD33 positive cells of 2 CML patients with TKI resistance in Jiangsu Province Hospital, and the influence of rapamycin on the positive expressions of p-mTOR and p-S6 in vitro.Results:Rapamycin in vitro inhibited the positive expressions of p-mTOR and p-S6 in CD33 positive cells. After 3 months of oral administration of rapamycin, the positive expressions of p-mTOR and p-S6 in CD33 positive cells were decreased, and the copy number of BCR-ABL fusion gene was also decreased simultaneously.Conclusion:Part of the resistance of CML patients to TKI may be related to the activation of intracellular signaling pathway of mTOR.